Discovery and Early Development of Adrenomedullin Pegol (BAY 1097761) for the Treatment of ARDS - First Disclosure
Johannes Koebberling
Senior Science Fellow, Bayer AG
The talk will present the design and synthesis and early development of Adrenomedullin Pegol, with special focus on the innovative Pro-Drug conncept developed for this project. The reliability of which will be demonstrated with early clinical data.
20yrs of experience as medicinal chemist at Bayer pharmaceuticals with increasing responsibilities - currently Senior Research Fellow.
Worked on multiple projects starting in combi-chem, peptide synthesis, diabetes and atherosclerosis research, a stint in Animal Health and currently with focus on Critical Care Medicine and LNPs for CGT.
Post-Doc with AGM Barrett at Imperial College, London, UK (Marie Curie fellowship). PhD and undergraduate education with Dieter Enders, RWTH Aachen, Germany.
>45 patents, >30 publications, 1 marketed drug